Abstract Purpose: The 21-gene Recurrence Score assay (Oncotype DX) provides prognostic/ predictive information in oestrogen receptor positive (ERþ) early breast cancer, but access/ reimbursement has been limited in most European countries in the absence of prospective outcome data. Recently, two large prospective studies and a real-life 5-year outcome study Results: The analysis demonstrated that treatment recommendations changed in 32% of patients post-testing; chemotherapy recommendation rate decreased from 55% to 34%. Change rates in the individual studies ranged from 30% to 37%. The highest change rates were in patients originally recommended chemotherapy and in grade II tumours; there was no subgroup without a treatment recommendation change. Notably, 31% of patients with an intermediate Recurrence Score result had a treatment recommendation change suggesting that testing provides actionable information in this group. With the exception of the German study (where chemotherapy rates remained high [41%] post-testing), between-study variability in treatment recommendations decreased post-testing (chemotherapy: from 36e52% to 26e29%; hormonal therapy: from 48e64% to 71e74%). Physicians' confidence regarding treatment recommendations improved in all the studies after testing. Conclusion: Recurrence Score testing led to changes in adjuvant chemotherapy use in approximately a third of patients, to an overall reduced chemotherapy use, and to more homogeneous decision making.
Introduction
Only a modest proportion of patients with oestrogen receptor positive (ERþ) human epidermal growth factor receptor 2 (HER2)enegative early breast cancer benefit from adjuvant chemotherapy [1] . Since currently used traditional markers are prognostic but not predictive of chemotherapy benefit, there is substantial overtreatment. The 21-gene Recurrence Score assay (the Oncotype DX â Breast Recurrence Score Assay; Genomic Health, Inc., Redwood City, CA) is a validated prognosticator (in ERþ node-negative and nodepositive early breast cancer patients) that provides independent prognostic information to traditional measures and has been shown to predict adjuvant chemotherapy benefit when tested in patients previously included in phase III clinical trials that randomised patients to hormonal therapy (HT) alone versus chemohormonal therapy (CHT) [1e6] .
Importantly, results from four recently published/ presented studies now confirm the available prospective retrospective validation data. The prospective phase III TAILORx adjuvant trial demonstrated that in nodenegative hormone receptor (HR)þ HER2-negative patients (n Z 1626) with low (10) Recurrence Score results treated with HT alone, distant-recurrence risk at 5 years was very low (0.7%) [7] . The prospective phase III WSG Plan B trial in patients with node-positive or highrisk node-negative HRþ HER2-negative disease showed that in this patient population too, the distant-recurrence risk is very low in patients (n Z 348) with Recurrence Score results 11 and HT alone (3-year event-free survival of 98.3%) [8] . The third study evaluated a large cohort (n Z 2028) of patients for whom treatment decisions incorporated the assay in real-life clinical practice [9] . It reported a 5-year rate of distant recurrence of 0.8% in patients with low Recurrence Score results (<18) treated with HT (2% chemotherapy use), a 3.2% rate in patients with intermediate scores (18e30) (25% chemotherapy use), and a 10.6% rate in patients with high scores (31) (88% chemotherapy use) [9] . The fourth study was a prospectively defined analysis of the Surveillance, Epidemiology, and End Results registry which was electronically supplemented with Recurrence Score results. It reported survival data only and demonstrated excellent 5-year breast cancer-specific survival in >21,000 node-negative HRþ HER2-negative breast cancer patients with low Recurrence Score results (99.6%) [10] .
The Recurrence Score assay is incorporated in major international guidelines such as the Despite inclusion in all major international guidelines, less than 20% of patients in Europe have access to the Recurrence Score assay through national reimbursement. Absence of outcome data from prospective studies as well as from real-life studies in patient populations that are using the assay to guide treatment decisions has been stated as the main cause for lack of reimbursement in many countries. Treatment recommendations in ERþ early breast cancer in European countries vary owing to different therapeutic traditions/ local guidelines. With prospective outcome data available, an increase in access and reimbursement is likely. Therefore, it is relevant to assess the impact of using the assay in different patient populations and countries. Here, we performed a pooled analysis in order to generate as robust data as possible regarding the impact of the assay on adjuvant treatment recommendations in node-negative ERþ, HER2-negative breast cancer in available prospective European decision impact studies. We evaluated the association between traditional parameters and assay-driven treatment recommendation changes and also compared treatment recommendations between study countries pre-and post-assay.
Methods

Patient population
The analysis included four European prospective studies finalised to date, according to the best knowledge of the authors. These similarly designed studies investigated the impact of Recurrence Score testing on clinical decisions in France, Germany, Spain, and the United Kingdom (UK) [15e18] . In these studies, consecutive patients with no contraindications to chemotherapy were enrolled, adjuvant treatment recommendations of the treating physician pre-and post-Recurrence Score testing were recorded, and the treating physicians completed questionnaires regarding their confidence in their treatment recommendations before/after testing.
All patients included in the final pooled analysis (n Z 527) were node negative, ERþ, HER2 negative and underwent Recurrence Score testing as per study protocols. Node-positive patients, patients with micrometastases, and those with no available Recurrence Score results were excluded (n Z 151) to provide a more homogeneous study population.
Statistical analysis
Analysis of variance/chi-squared tests were used to assess continuous/categorical parameters across studies. McNemar's test was used to assess whether the change (from pre-to post-testing) in the proportion of patients with CHT and HT recommendations was significant. Wilcoxon signed-rank test was used to assess whether the change (from pre-to post-testing) in physicians' confidence was significant.
Using logistic regression analysis, the probability of a treatment recommendation change was modelled as a function of the Recurrence Score category (as defined by Paik et al. [2] ), age (<55, 55 years; this cutoff value was chosen as a proxy for menopausal status), tumour size (2, >2 cm; i.e. T1 versus T2/T3), grade (IeIII), progesterone receptor (PR) status, and Ki-67 levels (<20%, 20%). Patients with missing data were excluded from the analysis. Stepwise regression analysis was performed to determine whether interactions between the evaluated covariates and the Recurrence Score result should be included in the model.
Results
Study patients
The analysis included 565 patients (French study, 83; Spanish study, 107; UK study, 131; and German study, 244). The patient populations were similar with respect to age and PR status and differed with respect to tumour size and grade (p < 0.0001, both variables) ( Table 1 ).
Recurrence Score distribution
A wide range of Recurrence Score results was observed in the pooled cohort ( Fig. 1 ) with a median (range) of 16 (0e81) and a mean (SD) of 18.1 (10.1) (p Z 0.19 for comparison across studies). The distribution of Recurrence Score categories differed across the studies (p Z 0.031) ( Table 1) .
The distribution of these Recurrence Score categories was similar in younger and older patients (<55, 55 years) and in patients with smaller and larger (2, >2 cm) tumours (p Z 0.37 and p Z 0.081, respectively); the distribution differed by grade (p < 0.0001) (Fig. 2 ).
Changes in treatment recommendations
Treatment recommendations before and after Recurrence Score testing were available for 527 patients. Pretesting, 45.4% were recommended CHT and 54.6% HT (Table 2) . Overall, 31.9% (95% confidence interval [CI], 27.9e35.9%) had a recommendation change posttesting. Of the CHT-recommended patients (pretesting), 48.1% (95% CI, 41.8e54.5%) were recommended HT post-testing; of the HT-recommended patients (pre-testing), 18.4% (95% CI, 13.9e22.9%) were recommended CHT post-testing. After knowing the assay results, the proportion of CHT-recommended patients decreased to 33.6% (net reduction: 26%; relative reduction: 38%); the proportion of HTrecommended patients increased to 66.4% (Table 2 ; p < 0.0001). Knowing the assay result impacted treatment recommendations for patients in all Recurrence Score grade, age, and tumour size groups (Table 2 ). Significant changes in the proportion of CHT-and HTrecommended patients were also observed in the low Recurrence Score group as defined in the TAILORx study (<11) [7] (Table 2 ). These changes were aligned with the Recurrence Score results: a decrease in CHT recommendations was observed in low Recurrence Score patients and an increase in high Recurrence Score patients. Upon dividing the intermediate Recurrence Score group into two subgroups (18e25, 26e30), an increase in CHT recommendation was observed in both subgroups (statistically significant in the former [p Z 0.0094] and trending in the latter [p Z 0.058]) ( Table 2 ). The data from the individual studies were similar to those of the pooled analysis with the proportions of patients with a treatment recommendation change ranging from 29.9 to 36.6% (Table 3) .
The changes in treatment recommendations (an overall decreased CHT and increased HT use) were statistically significant in the French, UK, and German studies (p < 0.0001, p Z 0.020, and p Z 0.047, respectively) and trending (p Z 0.086) in the Spanish study. With the exception of the German study, which was characterised by a relatively high proportion of CHT-recommended patients post-testing (41%), the between-study variability in the proportions of CHTand HT-recommended patients decreased post-testing (CHT: from 36.4e52.4% to 25.6e28.7%; HT: from 47.6e63.6% to 71.3e74.4%) (Fig. 3) .
In a univariate analysis, the association between the Recurrence Score category and change in treatment recommendation was significant for both a change from HT to CHT (odds ratio [OR], 30.5 for high Recurrence Score versus intermediate and low categories combined; 95% Wald CI, 6.5e142.6; p < 0.0001) and from CHT to HT (OR, 34.0 for low Recurrence Score versus intermediate and high categories combined; 95% Wald CI, 16.6e69.6; p < 0.0001).
A logistic regression analysis was used to model the probability of changing treatment recommendation as a function of the Recurrence Score category, age (<55, 55 years), tumour size (2, >2 cm), tumour grade (IeIII), PR status (positive, negative), and the interactions thereof, for patients who were initially recommended HT as well as for patients who were initially recommended CHT. The probability could not be modelled using all Recurrence Score categories because of the prominent impact of the high and low Recurrence Score results in patients who were initially recommended CHT and HT, respectively. Therefore, we combined the intermediate and high categories for the analysis of CHT to HT change and the low and intermediate categories for the analysis of HT to CHT change. In a stepwise regression analysis, the interaction of the Recurrence Score category and the other covariates was determined to be non-significant. For patients who were initially recommended CHT, having a low (versus high/intermediate) Recurrence Score result was associated with significantly higher odds of CHT to HT change, as was having a grade I or II tumours, being PR-positive, and having smaller tumours. For patients who were initially recommended HT, having a high (versus low/intermediate) Recurrence Score result was associated with significantly higher odds of HT to CHT change, as was being younger, having grade III tumours, and being PR-negative (Table 4) . In a logistic regression analysis using all the aforementioned covariates and Ki-67 levels (which were available only for 241 patients), only the Recurrence Score category was found to be a significant covariate in patients who were initially recommended CHT and none of the covariates were found to be significant in patients who were initially recommended HT.
In addition, we evaluated the correlation between Ki-67 and the Recurrence Score results in the 241 patients for whom both values were available and found a moderate Pearson correlation coefficient of 0.46.
The impact of testing on physicians' confidence regarding treatment recommendations
The four evaluated studies differed in the scale used to assess physicians' confidence regarding treatment recommendations. Therefore, these data were not pooled, and the analysis was performed for each study separately. Between 33.0% and 60.2% of physicians in the evaluated studies reported increased, 33.0e52.4% reported no change, and 6.8e14.9% reported decreased confidence regarding treatment recommendations (Fig. 4) . In all studies, knowing the Recurrence Score result was associated with a significant improvement in physicians' confidence regarding treatment recommendations (p < 0.01, all studies). Knowing the Recurrence Score result increased the physicians' confidence in the final treatment recommendation, regardless of whether the treatment recommendation changed or not.
Discussion
This pooled analysis of four prospective European studies demonstrated that despite differences in therapeutic traditions between countries, Recurrence Score testing significantly impacted adjuvant treatment recommendations and physicians' confidence about treatment recommendations in node-negative ERþ, HER2-negative breast cancer, with an overall change rate of 32% and a relative reduction in chemotherapy use of 38%. These results are consistent with findings from studies performed worldwide [19e26] , all showing a significant impact of testing on adjuvant treatment decisions with a change in approximately one third of patients. Table 3 The impact of knowing the Recurrence Score result on treatment recommendation by study. Treatment recommendations pre-testing were heterogeneous in the different studies with substantial differences in the proportion of patients with low, intermediate, and high Recurrence Score results being recommended chemotherapy. Post-testing, the betweenstudy variability decreased and treatment recommendations became more homogeneous, suggesting that broad use of the assay may reduce heterogeneity in treatment decisions. Health-economic (HE) studies from all evaluated markets show that broad use of the assay is cost effective (reviewed by Zanotti et al. [27] ). Nonetheless, from a medical as well as HE perspective, it is of interest to understand in which patients the assay has the highest utility. When assessing treatment recommendation change rates by subgroups, the highest change rate was seen in patients originally recommended chemotherapy (48.1%), grade II (37.3%), and younger patients (40.4%). Treatment recommendation changes were seen in a similar range of patients regardless of tumour size (2, >2 cm). Thus, it can be argued that from a HE perspective, the most important patient subgroups in which to use the assay include those originally recommended chemotherapy and those with grade II tumours. From a medical perspective, it is important to note that all the clinical categories listed above had a clinically relevant treatment Table 4 Odds ratios for changing treatment recommendations (logistic regression analysis). recommendation change rate. Therefore, limiting the use of the assay to patients originally recommended chemotherapy means that some patients that could be identified by the assay as having a high likelihood of benefitting from chemotherapy will not receive a treatment that could reduce their distant-recurrence risk.
It is sometimes argued that an intermediate Recurrence Score result is unhelpful. However, in our study, approximately a third (31.4%) of patients with intermediate results had a treatment recommendation change, demonstrating that intermediate results provide clinically actionable information. This is likely related to the fact that the Recurrence Score result is given on a continuous scale. Indeed, when the intermediate Recurrence Score group was divided into those with 18e25 and 26e30 Recurrence Score results, CHT recommendation rate increased more pronouncedly in the latter subgroup (relative increase of 37% versus 25%). The present data are consistent with studies from the United States and Israel showing that decisions in patients with intermediate results are determined primarily based on whether the result is low or high (within the intermediate range) with a strong increase in chemotherapy recommendations in patients with scores >25 and that other traditional factors such as grade, tumour size, and age also matter [9, 28, 29] . Notably, results from the Clalit study [9] where patients were not randomized to chemotherapy or no chemotherapy indicate that patients with Recurrence Score results of 25 or less without other high-risk features have little or no benefit from chemotherapy, although it should be noted that the results of TAILORx on the role of chemotherapy in intermediate Recurrence Score patients are pending. Ki-67 is used in many countries as a marker relevant for treatment decisions despite recent data highlighting substantial issues with reproducibility and data showing that the marker is not predictive of chemotherapy benefit [30, 31] . In this pooled analysis, many but not all patients had Ki-67 assessments available. The correlation between Ki-67 and the Recurrence Score result was modest, consistent with data from the WSG Plan B study [32] .
In conclusion, our findings demonstrate that the Recurrence Score has a substantial impact on treatment recommendations with an overall significant reduction in chemotherapy use. The consistency of the results from different countries underlines the utility of the Recurrence Score. The highest change rates were seen in patients originally recommended chemotherapy, in younger patients, and in patients with grade II, but there was no subgroup of patients that did not have a clinically relevant rate of change in treatment recommendations. Limiting the use of the Recurrence Score assay to the subgroups of patients with the highest change rate may be of HE interest due to cost effectiveness and can even be associated with cost savings. From a medical perspective, a broad use of the assay has the advantage of both reducing chemotherapy in those with minimal if any benefit, as well as identifying a smaller proportion of patients that are likely to have a substantial benefit from chemotherapy. A broad use of the assay will also reduce the substantial heterogeneity of treatment recommendations currently seen when using traditional markers.
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